Bevacizumab in combination with IFN-alfa in metastatic renal cell carcinoma: the AVOREN trial.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F12%3A33140649" target="_blank" >RIV/61989592:15110/12:33140649 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1586/era.12.103" target="_blank" >http://dx.doi.org/10.1586/era.12.103</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1586/era.12.103" target="_blank" >10.1586/era.12.103</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Bevacizumab in combination with IFN-alfa in metastatic renal cell carcinoma: the AVOREN trial.

Popis výsledku v původním jazyce

Metastatic renal cell carcinoma (mRCC) is tumor resistant to all cytotoxic agents. During the last decade, effective targeted therapies emerged including sunitinib, pazopanib and the combination of bevacizumab with IFN-alfa. The use of bevacizumab plus IFN-alfa combination in mRCC is supported by the AVOREN trial. Although the primary end point of the AVOREN trial was overall survival, progression-free survival was used to evaluate efficacy and served as the basis of regulatory submission owing to the advent of targeted agents that probably resulted in the prolongation of overall survival in both experimental and control arms. The doubling of median progression-free survival in the AVOREN trials (from 5.4 to 10.2 months) is remarkably similar comparedwith the results of Phase III trials with sunitinib and pazopanib. Bevacizumab plus IFN-alfa is the only combined regimen currently used in mRCC and serves as a comparator in the trials combining bevacizumab with other agents.

Název v anglickém jazyce

Bevacizumab in combination with IFN-alfa in metastatic renal cell carcinoma: the AVOREN trial.

Popis výsledku anglicky

Metastatic renal cell carcinoma (mRCC) is tumor resistant to all cytotoxic agents. During the last decade, effective targeted therapies emerged including sunitinib, pazopanib and the combination of bevacizumab with IFN-alfa. The use of bevacizumab plus IFN-alfa combination in mRCC is supported by the AVOREN trial. Although the primary end point of the AVOREN trial was overall survival, progression-free survival was used to evaluate efficacy and served as the basis of regulatory submission owing to the advent of targeted agents that probably resulted in the prolongation of overall survival in both experimental and control arms. The doubling of median progression-free survival in the AVOREN trials (from 5.4 to 10.2 months) is remarkably similar comparedwith the results of Phase III trials with sunitinib and pazopanib. Bevacizumab plus IFN-alfa is the only combined regimen currently used in mRCC and serves as a comparator in the trials combining bevacizumab with other agents.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert Review of Anticancer Therapy

ISSN

1473-7140

e-ISSN

—

Svazek periodika

12

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

1253-1261

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—